Drug Profile
Research programme: cystic fibrosis therapeutic - Travere Therapeutics
Alternative Names: RE-013Latest Information Update: 24 Nov 2020
Price :
$50
*
At a glance
- Originator Retrophin
- Developer Travere Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cystic fibrosis
Most Recent Events
- 16 Nov 2020 Retrophin is now called Travere Therapeutics
- 16 Jul 2016 No recent reports of development identified for research development in Cystic-fibrosis in USA
- 28 May 2012 Early research in Cystic fibrosis in USA (unspecified route)